Transparent reporting of missing outcome data in clinical trials: Applying the general principles of CONSORT 2010

Evidence-Based Medicine

Volumn 19, Issue 5, 2014, Pages 161-162

  Kistin, Caroline J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DATA PROCESSING; HUMAN; OUTCOME ASSESSMENT; CHECKLIST; METHODOLOGY; PRACTICE GUIDELINE; PUBLISHING; STANDARDS;

CHECKLIST; CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HUMANS; PUBLISHING; RESEARCH DESIGN;

EID: 84909983006     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2014-101797     Document Type: Article

References (20)

1. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003;348:2136-7.
2. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 2004;1:368-76.
3. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305-12.
4. Rabinowitz J, Levine SZ, Barkai O, et al. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 2009;35:775-88.
5. National Research Council. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press, 2010. http://www.nap.edu/catalog.php?record-id=12955
6. Lurie I, Levine SZ. Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD. J Nerv Ment Dis 2010;198:116-24.
7. Gehling M, Hermann B, Tryba M. Meta-analysis of dropout rates in randomized controlled clinical trials: opioid analgesia for osteoarthritis pain. Schmerz 2011;25:296-305.
8. DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for handling missing data in clinical trials. J Biopharm Stat 2009;19:1055-73.
9. Graham JW. Missing data analysis: making it work in the real world. Annu Rev Psychol 2009;60:549-76.
10. Vickers AJ, Altman DG. Statistics notes: missing outcomes in randomised trials. BMJ 2013; 346:f3438.
11. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012;91:550-4.
12. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials 2007;4:350-6.
13. Spratt M, Carpenter J, Sterne JA, et al. Strategies for multiple imputation in longitudinal studies. Am J Epidemiol 2010;172:478-87.
14. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 2010;29:2920-31.
15. Dziura JD, Post LA, Zhao Q, et al. Strategies for dealing with missing data in clinical trials: from design to analysis. Yale J Biol Med 2013;86:343-58.
16. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340:c332.
17. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
18. Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013; 346:e7586.
19. Hedeker D, Mermelstein RJ, Demirtas H. Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. Addiction 2007;102:1564-73.
20. Twardella D, Brenner H. Implications of nonresponse patterns in the analysis of smoking cessation trials. Nicotine Tob Res 2008;10:891-6.